$TLSA

Tiziana Life Sciences Ltd

Tiziana Life Sciences is a clinical-stage biotechnology company developing therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes candidates for non-active secondary progressive multiple sclerosis, multiple system atrophy, Alzheimer’s disease and amyotrophic lateral sclerosis. The company uses a lean, virtual research and development model with expert teams. Its lead candidate is Foralumab (TZLS-401), a fully human anti-CD3 monoclonal antibody being developed for intranasal administration, particularly for multiple sclerosis and other central nervous system indications. Tiziana also has TZLS-501, a fully human anti-IL-6 receptor antibody candidate for autoimmune, inflammatory and oncology indications; development of this and other assets is deprioritized while the company focuses on Foralumab. Tiziana develops drug candidates and holds development and commercialization rights to its product candidates. It is headquartered in London, England, United Kingdom.

1
0
0

No SEC Form 4 filings for $TLSA in the last 30 days.

See all $TLSA insider activity →
Low

Tiziana's Foralumab Hits Goals in MS Phase 2 Trial

Tiziana Life Sciences announced positive results from a phase 2 trial of Foralumab in secondary progressive multiple sclerosis. The trial met primary endpoints, showing reduced neuroinflammation and safety. Secondary endpoints, including fatigue and EDSS scores, also showed statistical significance. The company plans to advance the 50 microgram dose in future studies.

Tiziana Life Sciences Ltd.: Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference 2026 in London

Tiziana Life Sciences (TLSA) will present at the Jefferies Healthcare Conference in London on November 18, 2026. The company will discuss its Phase 2a INFORM-MS trial results for intranasal foralumab in non-active secondary progressive multiple sclerosis, which met primary endpoints and showed clinical improvements. Management will also be available for one-on-one meetings.

Tiziana’s nasal foralumab reduces microglial activation in progressive MS trial

Tiziana Life Sciences (TLSA) reported that its nasal foralumab reduced microglial activation in a Phase 2a trial for non-active secondary progressive multiple sclerosis. The 50 microgram dose showed significant reductions on TSPO PET imaging. Both doses improved fatigue, though the study wasn't powered for that endpoint. The company plans to discuss next steps with the FDA.

TLSA sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning TLSA (Tiziana Life Sciences Ltd). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent TLSA coverage spans financial news, technology and earnings.

What's driving TLSA

  • Tiziana Life Sciences announced positive results from a phase 2 trial of Foralumab in secondary progressive multiple sclerosis. The trial met primary endpoints, showing reduced neuroinflammation and safety. Secondary endpoints, including fatigue and EDSS scores, also showed statistical significance. The company plans to advance the 50 microgram dose in future studies.

    bioxconomy.com · Nov 16, 2026

  • Positive Phase 2a data for intranasal foralumab could boost the stock.

    finanznachrichten.de · Nov 12, 2026

  • Positive Phase 2a data may lift the stock as investors price in potential efficacy and future trial milestones.

    finance.yahoo.com · Nov 9, 2026

  • The data may lift sentiment but the modest size and early stage limit immediate price impact.

    tradingview.com · Nov 9, 2026

  • The announcement may generate modest buying interest as investors anticipate partnership funding or licensing deals for the foralumab program.

    finance.yahoo.com · Nov 9, 2026

AlphAI scores every news story that mentions TLSA with an AI model for sentiment and relevance, and aggregates insider trades from Tiziana Life Sciences Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $TLSA

Score

Tiziana's Foralumab Hits Goals in MS Phase 2 Trial

Tiziana Life Sciences announced positive results from a phase 2 trial of Foralumab in secondary progressive multiple sclerosis. The trial met primary endpoints, showing reduced neuroinflammation and safety. Secondary endpoints, including fatigue and EDSS scores, also showed statistical significance. The company plans to advance the 50 microgram dose in future studies.

Tiziana Life Sciences Ltd.: Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference 2026 in London

Tiziana Life Sciences (TLSA) will present at the Jefferies Healthcare Conference in London on November 18, 2026. The company will discuss its Phase 2a INFORM-MS trial results for intranasal foralumab in non-active secondary progressive multiple sclerosis, which met primary endpoints and showed clinical improvements. Management will also be available for one-on-one meetings.

Tiziana Life Sciences to advance foralumab partnering talks at BIO-Europe 2026

Tiziana Life Sciences (TLSA) will present its foralumab program at BIO-Europe 2026, aiming to advance partnering discussions after positive Phase 2a results in multiple sclerosis. CEO Ivor Elrifi will present, and the company will hold meetings with potential partners and investors. Discussions will focus on the Phase 2a INFORM-MS trial results and broader pipeline, including programs for Alzheimer's, multiple system atrophy, and ALS.

Tiziana's experimental MS treatment meets main goals in mid-stage study

Tiziana Life Sciences reported positive results from a mid-stage trial of its experimental MS treatment, foralumab. The therapy met primary endpoints, reducing brain inflammation and showing a favorable safety profile. Shares rose over 7% in premarket trading. The trial involved 48 patients across eight US sites, with no serious side effects reported.

Tiziana completes dosing in Phase 2 Alzheimer’s trial of intranasal foralumab

Tiziana Life Sciences (TLSA) completed dosing in its Phase 2 trial of intranasal foralumab for early or mild Alzheimer's, with topline data expected in Q1 2027. The trial, assessing safety, tolerability, and efficacy, includes foralumab alone and in combination with lecanemab or donanemab. Key endpoints include changes in neuroinflammation, cognitive function, and fluid biomarkers.

Market movers: HPE, Boeing, Salesforce, Tiziana Life

MongoDB (MDB) raised long-term growth targets, with Bank of America maintaining a Buy rating. Tiziana Life Sciences (TLSA) seeks FDA orphan drug designation for foralumab. Apple (AAPL) plans a Siri-powered smart-home hub. Salesforce (CRM) acquired Listen Labs, shares up 3.2%. Boeing (BA) won a multi-billion-dollar Navy contract. Conagra (CAG) shares fell 4.6% after Q1 revenue decline. HPE (HPE) shares rose 5% after a $1.2B order from Vultr.

Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)

Tiziana Life Sciences (TLSA) filed for FDA Orphan Drug Designation for intranasal foralumab to treat Multiple System Atrophy (MSA), a rare neurodegenerative disease. The company is conducting a Phase 2a trial. If granted, the designation could provide market exclusivity and other benefits. Foralumab is also being studied for other neuroinflammatory conditions.

Related tickers